A Live-Attenuated HSV-2 ICP0− Virus Elicits 10 to 100 Times Greater Protection against Genital Herpes than a Glycoprotein D Subunit Vaccine
Open Access
- 11 March 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (3) , e17748
Abstract
Glycoprotein D (gD-2) is the entry receptor of herpes simplex virus 2 (HSV-2), and is the immunogen in the pharmaceutical industry's lead HSV-2 vaccine candidate. Efforts to prevent genital herpes using gD-2 subunit vaccines have been ongoing for 20 years at a cost in excess of $100 million. To date, gD-2 vaccines have yielded equivocal protection in clinical trials. Therefore, using a small animal model, we sought to determine if a live-attenuated HSV-2 ICP0− virus would elicit better protection against genital herpes than a gD-2 subunit vaccine. Mice immunized with gD-2 and a potent adjuvant (alum+monophosphoryl lipid A) produced high titers of gD-2 antibody. While gD-2-immunized mice possessed significant resistance to HSV-2, only 3 of 45 gD-2-immunized mice survived an overwhelming challenge of the vagina or eyes with wild-type HSV-2 (MS strain). In contrast, 114 of 115 mice immunized with a live HSV-2 ICP0− virus, 0ΔNLS, survived the same HSV-2 MS challenges. Likewise, 0ΔNLS-immunized mice shed an average 125-fold less HSV-2 MS challenge virus per vagina relative to gD-2-immunized mice. In vivo imaging demonstrated that a luciferase-expressing HSV-2 challenge virus failed to establish a detectable infection in 0ΔNLS-immunized mice, whereas the same virus readily infected naïve and gD-2-immunized mice. Collectively, these results suggest that a HSV-2 vaccine might be more likely to prevent genital herpes if it contained a live-attenuated HSV-2 virus rather than a single HSV-2 protein.Keywords
This publication has 88 references indexed in Scilit:
- Diversity in CD8+ T Cell Function and Epitope Breadth Among Persons with Genital HerpesJournal of Clinical Immunology, 2010
- Rationalizing the development of live attenuated virus vaccinesNature Biotechnology, 2010
- The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigsVaccine, 2010
- Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff proteinVaccine, 2010
- ICP0 Antagonizes ICP4-Dependent Silencing of the Herpes Simplex Virus ICP0 GenePLOS ONE, 2010
- Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigsBMC Microbiology, 2010
- Protection from Herpes Simplex Virus (HSV)–2 Infection with Replication‐Defective HSV‐2 or Glycoprotein D2 Vaccines in HSV‐1–Seropositive and HSV‐1–Seronegative Guinea PigsThe Journal of Infectious Diseases, 2009
- Potent Adjuvant Activity of Cationic Liposome-DNA Complexes for Genital Herpes VaccinesClinical and Vaccine Immunology, 2009
- A Replication-Competent, Neuronal Spread-Defective, Live Attenuated Herpes Simplex Virus Type 1 VaccineJournal of Virology, 2008
- Diversity of the CD8+T-Cell Response to Herpes Simplex Virus Type 2 Proteins among Persons with Genital HerpesJournal of Virology, 2006